Interfacially activated aggregation of alpha-synuclein

Information

  • Research Project
  • 9011621
  • ApplicationId
    9011621
  • Core Project Number
    R56NS081251
  • Full Project Number
    1R56NS081251-01A1
  • Serial Number
    081251
  • FOA Number
    PA-13-302
  • Sub Project Id
  • Project Start Date
    3/15/2015 - 9 years ago
  • Project End Date
    2/28/2017 - 7 years ago
  • Program Officer Name
    SUTHERLAND, MARGARET L
  • Budget Start Date
    3/15/2015 - 9 years ago
  • Budget End Date
    2/28/2017 - 7 years ago
  • Fiscal Year
    2015
  • Support Year
    01
  • Suffix
    A1
  • Award Notice Date
    3/9/2015 - 9 years ago

Interfacially activated aggregation of alpha-synuclein

? DESCRIPTION (provided by applicant): Aggregation and fibrillization of ?-synuclein has been implicated in the progression of Parkinson's Disease, which currently has no cure. This research project is focussed on the molecular steps for initiation of ?-synuclein aggregation and fibrillization. The project builds on the PI's discovery that ?-synuclein appears resistant to aggregation except when exposed to non-fluid hydrophobic interfaces or to preformed seeds. The research uses chemically functionalized silica substrates to measure ?-synuclein conformation at the interface, and uses identically functionalized mixing balls to assay for the interfacial influence on aggregation and fibrillization. This platform allows systematic evaluation of the relationship between the physical and chemical properties of the interface, the conformational changes in ?-synuclein, and the initiation of aggregation and fibrillization. The research will identify the physical and chemical properties of interface and the changes in ?-synuclein structure that lead to aggregation and fibrillization. The project then builds on the identification of that first step of aggregation and fibrillization to develop a fluorescence assayfor the changes in ?-synuclein that occur during the first step(s). The assay is intended to enable single-molecule sensitivity. The assay will be used to learn more about the first steps of ?-synuclein aggregation and fibrillization. To evaluate the hypothesis that ?-synuclein resists fibrillization without a nucleation partner, samples free from nucleating interfaces will be evaluated to try to find conditions for fibrillization that do not include nucleating parnters. Fially the fluorescence assays developed to probe the first steps of aggregation leading to fibrillization will be used to evaluate macromolecular binding partners. The macromolecules will be classified using the assay according to the type of structure they induce in ?-synuclein and how they inhibit or promote aggregation and fibrillization. These assays will evaluated for their future utiity as discovery reagents for ?-synuclein binding partners in cell lysates.

IC Name
NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
  • Activity
    R56
  • Administering IC
    NS
  • Application Type
    1
  • Direct Cost Amount
    225000
  • Indirect Cost Amount
    58164
  • Total Cost
    283164
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    853
  • Ed Inst. Type
    SCHOOLS OF ARTS AND SCIENCES
  • Funding ICs
    NINDS:283164\
  • Funding Mechanism
    Non-SBIR/STTR RPGs
  • Study Section
    MSFB
  • Study Section Name
    Macromolecular Structure and Function B Study Section
  • Organization Name
    MONTCLAIR STATE UNIVERSITY
  • Organization Department
    CHEMISTRY
  • Organization DUNS
    053506184
  • Organization City
    MONTCLAIR
  • Organization State
    NJ
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    070431624
  • Organization District
    UNITED STATES